Already have a subscription?Sign In
Log in to see the full chart
Log in to see the full chart
June 11, 2024
US Employers’ and Health Plans’ Coverage of GLP-1 Drugs for Type 2 Diabetes and Obesity, June 2024 (% of respondents)
Methodology
Data is from the June 2024 Pharmaceutical Strategies Group (PSG) "Trends in Drug Benefit Design Report." 223 benefits leaders representing US employers, health plans, and unions/Taft-Hartley plans were surveyed during February 15, 2024-March 15, 2024. Employers made up the largest portion of the sample (66%), followed by health plans (29%). The survey's primary source of respondents was PSG's proprietary database of drug benefit decision-makers.Featured In
New GLP-1 users are more likely to have obesity than diabetes Eli Lilly reports $11.3B in global Q2 revenue, raises guidance by $3BRo launches GLP-1 insurance coverage checkerEli Lilly’s tirzepatide reduces diabetes risk by 94% for some patients Elevance requests repayment from doctors for overprescribing Ozempic 9amHealth taps Instacart to integrate food prescriptions into its weight loss programs Consumers overspent by $200M on weight loss medications in the past yearNovo Nordisk moves into the D2C market with steep price reduction of WegovyChart Title
US Employers’ and Health Plans’ Coverage of GLP-1 Drugs for Type 2 Diabetes and Obesity, June 2024 (% of respondents)Publication Date
June 11, 2024